Ali K, Berman G, Zhou H, et al. - This ongoing phase 2–3, placebo-controlled trial revealed an acceptable safety profile of the mRNA-1273 vaccine in adolescents. It induced comparable immune responses to young adults, and was efficacious in preventing Covid-19.

• A total of 3,732 healthy adolescents (12 to 17 years of age) were administered two injections of the mRNA-1273 vaccine (100 μg in each) or placebo, 28 days apart.

• There were no serious adverse events linked to mRNA-1273 or placebo.

• In adolescents relative to young adults, the geometric mean titer ratio of pseudovirus neutralizing antibody titers was 1.08, and the absolute difference in serologic response was 0.2 percentage points, which met the non inferiority criterion.

• The mRNA-1273 group had no development of cases of Covid-19 with an onset of 14 days after the second injection, while the placebo group had an occurrence of four cases.